Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Ann Rheum Dis ; 69(8): 1562-7, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20542964

RESUMEN

BACKGROUND: Patients with rheumatoid arthritis (RA) have a systemic Th1 defect associated with inflammation. OBJECTIVE: To examine the hypothesis that interleukin 17 (IL-17) contributes to this defect. METHODS: IL-17 effects on Th1 markers were examined on T-bet and interferon gamma (IFNgamma) expression in peripheral blood mononuclear cells (PBMCs) from patients with RA or healthy controls (HC). Receptor specificities were determined by analysis of the Th1-specific IL-12 receptor beta2 (IL-12Rbeta2), Th17-specific IL-23R and the common IL-12Rbeta1 chain expression. Effects of IL-17 or IFNgamma on IL-6, IL-1, IL-8, matrix metalloproteinase-8 (MMP-8) were measured by real-time RT-PCR in RA synovial cells. RESULTS: RA PBMCs were less responsive to IL-12-induced IFNgamma than HC PBMCs. IL-12 hyporesponsiveness was increased by IL-17 treatment associated with a selective reduction in IL-12Rbeta2, but not IL-23R, IL-12Rbeta1 or T-bet, which was reversed with IL-17R inhibition. IL-17 inhibited IL-12Rbeta2 expression in developing Th1 cells. In RA synovial cells, IL-17 induced IL-6, IL-1, IL-8 and MMP-8, whereas IFNgamma had minimal or inhibitory effects. CONCLUSION: In RA, IL-12 hyporesponsiveness is associated with IL-17R-mediated downregulation of IL-12Rbeta2 expression. IL-17 may reinforce Th17 lineage commitment and proinflammatory and destructive effects through Th1 inhibition and positive feedback effects in RA synovial cells. Anti-inflammatory effects of IL-17/IL-17R antagonism may include the restoration of protective Th1 responses.


Asunto(s)
Artritis Reumatoide/inmunología , Interleucina-17/inmunología , Receptores de Interleucina-12/antagonistas & inhibidores , Células TH1/inmunología , Adulto , Comunicación Celular/inmunología , Diferenciación Celular/inmunología , Células Cultivadas , Regulación hacia Abajo/inmunología , Femenino , Humanos , Interferón gamma/biosíntesis , Interferón gamma/genética , Masculino , Persona de Mediana Edad , Monocitos/inmunología , ARN Mensajero/genética , Receptores de Interleucina-12/inmunología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Membrana Sinovial/inmunología , Proteínas de Dominio T Box/biosíntesis
2.
Cytokine ; 48(3): 226-30, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19692269

RESUMEN

Th17 cells are critical in adaptive immunity and autoimmune disease. The polarized development of Th17, Th1 and Th2 cells is dependent on counterregulatory effects on each other. Whereas IFN-gamma inhibits Th17 development, the effect of IL-17 in human Th1 development is not known. We report a novel negative regulatory role of IL-17 on IL-12R beta 2 expression associated with reduced IL-12 responsiveness. IL-17 decreased IL-12-induced IFN-gamma expression in PBMC and developing Th1 cells, associated with a selective reduction in IL-12R beta 2, and not IL-23R, IL-12R beta 1 or T-bet. Counterregulatory effects of human Th17 on Th1 lineage cytokines may contribute to lineage divergence. In autoimmune disease, IL-17 may reinforce its own developmental programme by reducing IL-12 responsiveness, thus limiting inhibitory effects of IFN-gamma on Th17 development.


Asunto(s)
Diferenciación Celular/efectos de los fármacos , Regulación hacia Abajo/efectos de los fármacos , Subunidad beta 2 del Receptor de Interleucina-12/metabolismo , Interleucina-17/farmacología , Células TH1/efectos de los fármacos , Células Cultivadas , Humanos , Subunidad beta 2 del Receptor de Interleucina-12/genética , Leucocitos Mononucleares/efectos de los fármacos , ARN Mensajero/metabolismo , Estándares de Referencia , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA